Teriparatide, a recombinant human parathyroid hormone (PTH) analog, is a synthetic peptide corresponding to the active 1-34 fragment of endogenous parathyroid hormone. Its CAS registry number is 52232-67-4. Comprising 34 amino acids, teriparatide has a molecular weight of approximately 4,117.8 daltons and is produced using recombinant DNA technology.
Teriparatide acts as an anabolic agent for bone by selectively stimulating osteoblast activity, enhancing bone formation, and improving bone mineral density. It also regulates calcium and phosphate metabolism. Clinically, it is primarily used to treat severe osteoporosis in postmenopausal women and men at high risk of fractures, as well as glucocorticoid-induced osteoporosis.
Administered via daily subcutaneous injections, teriparatide is typically prescribed for up to 24 months due to safety concerns linked to long-term use (e.g., potential osteosarcoma risk observed in animal studies). It is a key alternative to antiresorptive therapies like bisphosphonates, offering unique benefits for patients with compromised bone integrity.
Beyond osteoporosis, teriparatide is researched for applications in bone healing and rare metabolic bone disorders. As a controlled prescription drug, its use requires strict medical oversight to balance efficacy with potential side effects, such as hypercalcemia.
